<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mitoxantrone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mitoxantrone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mitoxantrone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10956" href="/d/html/10956.html" rel="external">see "Mitoxantrone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12617" href="/d/html/12617.html" rel="external">see "Mitoxantrone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709094"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mitoxantrone should be administered under the supervision of a health care provider experienced in the use of cytotoxic chemotherapy agents.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Appropriate administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mitoxantrone should be given slowly into a freely flowing intravenous (IV) infusion. It must never be given subcutaneously, intramuscularly (IM), or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. Not for intrathecal use. Severe injury with permanent sequelae can result from intrathecal administration.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Except for the treatment of acute nonlymphocytic leukemia, mitoxantrone therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm<sup>3</sup>. In order to monitor the occurrence of bone marrow suppression (primarily neutropenia, which may be severe and result in infection), it is recommended that frequent peripheral blood cell counts be performed on all patients receiving mitoxantrone.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiotoxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Congestive heart failure (CHF), potentially fatal, may occur during therapy with mitoxantrone or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative mitoxantrone dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In patients with cancer, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m<sup>2</sup>. To mitigate the cardiotoxicity risk with mitoxantrone, consider the following:</p>
<p style="text-indent:-2em;margin-left:6em;">All patients should be assessed for cardiac signs and symptoms by history, physical examination, and electrocardiogram (ECG) prior to start of mitoxantrone therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">All patients should have baseline quantitative evaluation of left ventricular ejection fraction (LVEF) using appropriate methodology (eg, echocardiogram, multigated radionuclide angiogram [MUGA], magnetic resonance imaging [MRI]).</p>
<p style="text-indent:-2em;margin-left:6em;">Multiple sclerosis (MS) patients with a baseline LVEF below the lower limit of normal should not be treated with mitoxantrone.</p>
<p style="text-indent:-2em;margin-left:6em;">MS patients should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to each dose.</p>
<p style="text-indent:-2em;margin-left:6em;">MS patients should undergo quantitative reevaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF. Additional doses of mitoxantrone should not be administered to MS patients who have experienced a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">MS patients should not receive a cumulative mitoxantrone dose greater than 140 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">MS patients should undergo yearly quantitative LVEF evaluation after stopping mitoxantrone to monitor for late-occurring cardiotoxicity.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Secondary leukemia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:4em;">Mitoxantrone therapy in patients with MS and in patients with cancer increases the risk of developing secondary acute myeloid leukemia.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F197618"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anthracenedione;</li>
<li>
                        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F197573"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Mitoxantrone usually should not be administered if baseline neutrophil count &lt;1,500/mm<sup>3</sup> (except for in the treatment of acute myeloid leukemia). Administer antihyperuricemic therapy and aggressive hydration as indicated. Actively manage modifiable cardiac risk factors (smoking, hypertension, diabetes, dyslipidemia, obesity) before initiating mitoxantrone treatment for patients with cancer (ASCO [Armenian 2017]).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="325fe1c9-065e-450c-9429-246476af14bd">Acute lymphoblastic leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, relapsed/refractory (off-label use):</b>
<b>IV:</b> 10 mg/m<sup>2</sup> on days 3 and 10 (in combination with fludarabine and cytarabine [FLAM regimen]) (Giebel 2006) <b>or</b> 8 mg/m<sup>2</sup> on days 1 to 3 (in combination with etoposide, ifosfamide, and mesna) as induction therapy; if complete remission occurred following induction, 1 additional cycle as consolidation therapy was administered (Schiller 1993).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59b0321d-4893-400e-859e-edc157b0b40c">Acute myeloid leukemias, initial therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemias, initial therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AML induction:</i>
<b>IV:</b> 12 mg/m<sup>2</sup> once daily for 3 days (in combination with cytarabine); for incomplete response, may repeat (7 to 10 days later) at 12 mg/m<sup>2</sup> once daily for 2 days (in combination with cytarabine) (Arlin 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AML consolidation</i> (beginning ~6 weeks after initiation of the final induction course): <b>IV: </b>12 mg/m<sup>2</sup> once daily for 2 days (in combination with cytarabine), repeat in 4 weeks (Arlin 1990).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f67ba0dd-7fb1-46ed-8cd1-3d903c74c998">Acute myeloid leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia, relapsed/refractory (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CLAG-M regimen:</i>
<b> IV: </b>10 mg/m<sup>2</sup> once daily for 3 days on days 1, 2, and 3 (in combination with cladribine, cytarabine, and filgrastim), may repeat once if needed (Wierzbowska 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>MEC regimen: </i>
<b>IV: </b>6 mg/m<sup>2</sup> once daily for 6 days on days 1 to 6 (in combination with cytarabine and etoposide) (Amadori 1991).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mitoxantrone/Etoposide:</i>
<b>IV:</b> 10 mg/m<sup>2</sup> once daily for 5 days on days 1 to 5 (in combination with etoposide) (Ho 1988).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8041dec1-0e04-4d6f-8017-2306fb5f968b">Acute promyelocytic leukemia, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute promyelocytic leukemia, newly diagnosed (off-label use):</b> Consolidation: <b>IV:</b> 10 mg/m<sup>2</sup> once daily for 5 days on days 1 to 5 of consolidation course 2 (in combination with tretinoin all-trans retinoic acid; ATRA [tretinoin]) (Sanz 2004); for low- and intermediate-risk patients the mitoxantrone dose has been reduced to 10 mg/m<sup>2</sup> once daily for 3 days on days 1 to 3 of consolidation course 2 (in combination with ATRA) (Sanz 2010).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Relapsed or refractory Hodgkin lymphoma:</b>
<i> MINE-ESHAP regimen:</i>
<b>IV:</b> 10 mg/m<sup>2</sup> on day 1 every 28 days for up to 2 cycles (MINE is combination with mesna, ifosfamide, mitoxantrone, and etoposide; MINE alternates with ESHAP for up to 2 cycles of each) (Fernandez de Larrea 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Newly diagnosed Hodgkin lymphoma, reduced intensity regimen:</b> Adults ≥66 years of age: <i>VEPEMB regimen:</i>
<b>IV: </b>6 mg/m<sup>2</sup> on day 15 every 28 days (in combination with vinblastine, cyclophosphamide, procarbazine, etoposide, and bleomycin) for 3 to 6 cycles (Levis 2004).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33c796a4-059c-4a7d-914b-04f1c2849b81">Multiple sclerosis, relapsing or secondary progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing or secondary progressive (alternative agent):</b>
<b>Note</b>: Reserve use for rapidly advancing, refractory multiple sclerosis (MS) (AAN [Rae-Grant 2018]; Olek 2019). In high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other appropriate specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]). Mitoxantrone generally should not be administered to patients with MS with neutrophil counts &lt;1,500 cells/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 12 mg/m<sup>2</sup> every 3 months (maximum lifetime cumulative dose: 140 mg/m<sup>2</sup>; discontinue with LVEF &lt;50% or clinically significant reduction in LVEF).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a689711-410d-4e68-a78f-8a93ba1c3bb2">Non-Hodgkin lymphomas, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas, relapsed or refractory (off-label use): </b>
<i>B-cell lymphomas: R-MINE regimen: </i>
<b>IV:</b> 8 mg/m<sup>2</sup> on day 1 (in combination with rituximab, mesna, ifosfamide, and etoposide) for up to 3 cycles (Joyce 2003).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f0691034-8b5d-491b-8b54-2a05ba4bee19">Prostate cancer, advanced, castrate-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced, castrate resistant:</b>
<b>IV:</b> 12 mg/m<sup>2</sup> once every 3 weeks (in combination with prednisone or prednisolone) for up to 10 cycles (Tannock 2004) <b>or</b> 12 to 14 mg/m<sup>2</sup> once every 3 weeks (in combination with prednisone) until disease progression or unacceptable toxicity, up to a maximum cumulative mitoxantrone dose of 144 mg/m<sup>2</sup> (Petrylak 2004).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c5acfef-6596-497f-90bd-63216cb2807e">T-cell prolymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>T-cell prolymphocytic leukemia (off-label use): </b>
<i>FMC-A regimen: </i>
<b>IV:</b> 8 mg/m<sup>2</sup> on day 1 every 28 days (in combination with fludarabine and cyclophosphamide [FMC]) for 2 to 4 cycles; if response demonstrated after initial 2 FMC cycles, then an additional 2 cycles of FMC were administered, followed by alemtuzumab consolidation; if stable disease or progression observed after initial 2 FMC cycles, then proceeded directly to alemtuzumab (Hopfinger 2013).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990563"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, in patients receiving mitoxantrone for the treatment of cancer, no need for dosage adjustment is expected (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> In patients receiving mitoxantrone for the treatment of cancer, no need for dosage adjustment is expected (Krens 2019).</p></div>
<div class="block doha drugH1Div" id="F50987910"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered hepatic function:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, clearance is reduced in hepatic dysfunction. Patients with severe hepatic dysfunction (bilirubin &gt;3.4 mg/dL) have an AUC of 3 times greater than patients with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosage adjustment recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Multiple sclerosis:</i> Patients with multiple sclerosis with hepatic impairment should not receive mitoxantrone.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients receiving mitoxantrone for the treatment of cancer:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Altered hepatic function:</b> Consider dosage adjustments (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Mild or moderate hepatic impairment:</b> No need for dosage adjustment is expected (Krens 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Severe hepatic impairment:</b> Consider reducing dose to 50% of the original dose (Krens 2019).</p></div>
<div class="block doo drugH1Div" id="F20342779"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (ASCO [Griggs 2021]).</p></div>
<div class="block dot drugH1Div" id="F7289331"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>AML:</b> Severe or life-threatening nonhematologic toxicity: Withhold treatment until toxicity resolves.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>MS:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Neutrophils &lt;1,500/mm<sup>3</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Signs/symptoms of HF: Evaluate for cardiac signs/symptoms and monitor LVEF.</p>
<p style="text-indent:-2em;margin-left:4em;">LVEF &lt;50% or baseline LVEF below the lower limit of normal (LLN): Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiotoxicity</b>
<b> in patients receiving mitoxantrone for treatment of cancer:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Asymptomatic heart disease:</i> Consider initiating heart failure medications (eg, an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and/or beta-blockers) in patients with asymptomatic (stage B) heart disease (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild cardiac dysfunction: </i>Continue treatment with close cardiovascular monitoring (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate cardiac dysfunction: </i>Interrupt treatment and utilize a multidisciplinary approach when deciding if/when to restart (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptomatic heart disease:</i> Initiate heart failure medications (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild cardiac dysfunction: </i>Consider a multidisciplinary approach for decisions regarding treatment interruption versus continuation (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate cardiac dysfunction: </i>Interrupt treatment; consider a multidisciplinary approach for decisions regarding treatment reinitiation (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe cardiac dysfunction: </i>Discontinue anthracycline therapy (ESC [Lyon 2022]).</p></div>
<div class="block doe drugH1Div" id="F197574"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F197596"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12617" href="/d/html/12617.html" rel="external">see "Mitoxantrone: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing regimens may vary by dose, cycles, and combination therapy; refer to individual protocols.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dbf77f7c-5262-4a97-bf90-7aa74defaa19">Acute lymphocytic leukemia, relapsed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia (ALL), relapsed:</b> Limited data available: Children and Adolescents: Induction: 10 mg/m<sup>2</sup>/dose once daily on days 1 and 2 (in combination with dexamethasone, vincristine, pegaspargase, and intrathecal methotrexate), with follow-up therapy (allogeneic stem cell transplant or continued chemotherapy) determined by risk stratification (Parker 2010)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0616790-4d1f-431a-acc0-3bce79aef7bb">Acute myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia (AML):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gamis 2014</i>: Infants, Children, and Adolescents: <b>Note:</b> Some aspects of protocol dosing presented in previous reports (Cooper 2012)</p>
<p style="text-indent:-2em;margin-left:6em;">Intensification Course 2:</p>
<p style="text-indent:-2em;margin-left:8em;">BSA &lt;0.6 m<sup>2</sup>: IV: 0.4 mg/<b>kg</b> once daily for 4 days on Days 3 to 6 of a 28-day cycle (in combination with cytarabine)</p>
<p style="text-indent:-2em;margin-left:8em;">BSA ≥0.6 m<sup>2</sup>: IV: 12 mg/m<sup>2</sup> once daily for 4 days on Days 3 to 6 of a 28-day cycle (in combination with cytarabine)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Perel 2002</i>: LAME 89/91 regimen: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Remission Induction:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;1 year: IV: 8 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine); if persistent disease, additional course of 8 mg/m<sup>2</sup> for 2 days (in combination with cytarabine) was administered</p>
<p style="text-indent:-2em;margin-left:8em;">≥1 year: IV: 12 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine); if persistent disease, additional course of 12 mg/m<sup>2</sup> for 2 days (in combination with cytarabine) was administered</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gibson 2011: </i>MAE and MidAC regimens:</p>
<p style="text-indent:-2em;margin-left:6em;">Induction Course 1 (MAE 3+10+5) or Course 2 (MAE 3+8+5):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants: IV: 9 mg/m<sup>2</sup> once daily on Days 1, 3, and 5 (in combination with cytarabine and etoposide)</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents &lt;17 years: IV: 12 mg/m<sup>2</sup> once daily on Days 1, 3, and 5 (in combination with cytarabine and etoposide)</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation Course 4/5 (MidAC):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants: IV: 7.5 mg/m<sup>2</sup> once daily on Days 1 to 5 (in combination with cytarabine)</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents &lt;17 years: IV: 10 mg/m<sup>2</sup> once daily on Days 1 to 5 (in combination with cytarabine)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f133373-607c-467b-8bff-de6df2e90e5c">Acute promyelocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute promyelocytic leukemia (APL):</b> Limited data available: Consolidation Course 2: Children ≥2 years and Adolescents: IV: 10 mg/m<sup>2</sup> once daily for 5 days of a 28-day cycle (combined with tretinoin [ATRA]) (Ortega 2005; Sanz 2004)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Oncology uses: Severe or life-threatening nonhematologic toxicity: Withhold treatment until toxicity resolves</p>
<p style="text-indent:-2em;margin-left:6em;">Multiple sclerosis:</p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils &lt;1,500/mm<sup>3</sup>: Use is not recommended</p>
<p style="text-indent:-2em;margin-left:8em;">Signs/symptoms of HF: Evaluate for cardiac signs/symptoms and monitor LVEF</p>
<p style="text-indent:-2em;margin-left:8em;">LVEF &lt;50% or baseline LVEF below the lower limit of normal (LLN): Use is not recommended</p></div>
<div class="block dorp drugH1Div" id="F51159481"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; refer to individual protocols; based on experience in adults, supplemental doses are not necessary with hemodialysis or peritoneal dialysis.</p></div>
<div class="block dohp drugH1Div" id="F51159482"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; refer to individual protocols. Based on experience in adults, clearance is reduced in hepatic dysfunction; patients with severe hepatic dysfunction (bilirubin &gt;3.4 mg/dL) have an AUC of 3 times greater than patients with normal hepatic function; consider dose adjustments.</p></div>
<div class="block adr drugH1Div" id="F197536"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Includes events reported with any indication; incidence varies based on treatment, dose, and/or concomitant medications.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (10% to 30%), cardiac disease (≤18%), cardiac arrhythmia (3% to 18%), ECG changes (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Pain (8% to 41%), fatigue (≤39%), headache (6% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (20% to 61%), nail bed changes (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Menstrual disease (26% to 61%), amenorrhea (28% to 53%), hyperglycemia (10% to 31%), weight gain (≤17%), weight loss (≤17%), increased gamma-glutamyl transferase (3% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (26% to 76%), vomiting (6% to 72%), diarrhea (14% to 47%), mucositis (10% to 29%; onset: ≤1 week), stomatitis (8% to 29%; onset: ≤1 week), anorexia (22% to 25%), constipation (10% to 16%), gastrointestinal hemorrhage (2% to 16%), abdominal pain (9% to 15%), dyspepsia (5% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (7% to 32%), hematuria (≤11%), urine abnormality (5% to 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (79% to 100%; onset: ≤3 weeks; grade 4: 23% to 54%), leukopenia (9% to 100%), lymphocytopenia (72% to 95%), anemia (≤75%), decreased hemoglobin (≤75%), thrombocytopenia (33% to 39%; grades 3/4: 3% to 4%), bruise (≤11%), febrile neutropenia (≤11%), petechia (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (≤37%), increased serum transaminases (5% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (4% to 60%), sepsis (≤34%), fungal infection (9% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (≤24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (≤22%), increased serum creatinine (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (7% to 53%), pharyngitis (≤19%), dyspnea (6% to 18%), cough (5% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (6% to 78%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac failure (≤5%), ischemia (≤5%), decreased left ventricular ejection fraction (≤5%), hypertension (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills (≤5%), anxiety (5%), depression (5%), seizure (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≤9%), skin infection (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (10%), hypokalemia (7% to 10%), hyponatremia (9%), hypermenorrhea (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Aphthous stomatitis (≤10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (≤7%), proteinuria (≤6%), sterility (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granulocytopenia (6%), hemorrhage (5% to 6%), acute leukemia (≤3%; secondary; includes AML, APL)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (cutaneous: ≤10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (6% to 8%), arthralgia (≤5%), myalgia (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (≤5%), blurred vision (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure (≤8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (10%), pneumonia (≤9%), sinusitis (≤6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, chest pain, dehydration, hypersensitivity reaction, interstitial pneumonitis (with combination chemotherapy), hyperuricemia, hypotension, ocular discoloration (blue discoloration of sclera), phlebitis (at infusion site), skin rash, tachycardia, urine discoloration (blue-green), urticaria</p></div>
<div class="block coi drugH1Div" id="F197550"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mitoxantrone or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Prior hypersensitivity to anthracyclines; prior substantial anthracycline exposure (if abnormal cardiac function prior to initiation of mitoxantrone therapy); presence of severe myelosuppression due to prior chemo- and/or radiotherapy; severe hepatic impairment; intrathecal administration.</p></div>
<div class="block war drugH1Div" id="F197533"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Mitoxantrone may lead to severe myelosuppression (at any dose). Unless the expected benefit outweighs the risk, mitoxantrone is generally not recommended in patients with preexisting myelosuppression due to prior chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Mitoxantrone is an irritant with vesicant-like properties. For IV administration only into a free-flowing IV; may cause severe local tissue damage if extravasation occurs. Extravasation resulting in burning, erythema, pain, swelling, and skin discoloration (blue) has been reported; may result in tissue necrosis and require debridement for skin graft. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: May contain sodium metabisulfite, which is associated with allergic-type reactions (including anaphylactic symptoms and potentially severe asthmatic episodes). The risk for hypersensitivity is higher in patients with asthma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: When using for the treatment of multiple sclerosis in high-risk populations or in countries with high tuberculosis burden, screen for latent infections (eg, hepatitis, tuberculosis) prior to initiating therapy. For patients who screen positive for latent infections, consult infectious disease or other specialists (eg, liver specialists) regarding treatment options before initiating therapy (AAN [Farez 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myocardial toxicity: May cause myocardial toxicity and potentially fatal heart failure (HF); risk increases with cumulative dosing. Cardiotoxicity may occur during therapy or may be delayed (months or years after completion of therapy). Predisposing factors for mitoxantrone-induced cardiotoxicity include prior anthracycline or anthracenedione therapy, prior or current cardiovascular disease, concomitant use of cardiotoxic drugs, and mediastinal/pericardial irradiation, although may also occur in patients without risk factors. Mitoxantrone is not recommended for use in patients with MS when baseline LVEF below the lower limit of normal (LLN). Evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) in patients with MS prior to each dose. Patients with MS should not receive a cumulative dose of &gt;140 mg/m<sup>2</sup>. Do not administer mitoxantrone if LVEF falls below LLN or if a significant decrease in LVEF is observed during treatment. Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity. Evaluate potential risk versus benefit in patients who have previously received anthracycline therapy. If signs/symptoms of heart failure develop, evaluate LVEF and ECG.</p>
<p style="text-indent:-2em;margin-left:6em;">- According to ASCO guidelines for prevention and monitoring of cardiac dysfunction in survivors of adult cancers (ASCO [Armenian 2017]), the risk of cardiac dysfunction is increased with high-dose anthracycline therapy (eg, equivalent to doxorubicin ≥250 mg/m<sup>2</sup>); high-dose radiotherapy (≥30 Gy) with the heart in the treatment field; lower-dose anthracyclines (eg, equivalent to doxorubicin &lt;250 mg/m<sup>2</sup>) in combination with lower-dose radiotherapy (&lt;30 Gy) with the heart in the treatment field; lower-dose anthracyclines AND any of the following risk factors: ≥2 cardiovascular risk factors (including smoking, hypertension, diabetes, dyslipidemia, and obesity) during or after completion of therapy or ≥60 years of age at cancer treatment, or compromised cardiac function (eg, borderline low LVEF [50% to 55%], history of myocardial infarction, moderate or higher valvular heart disease) before or during treatment; treatment with lower-dose anthracycline followed by trastuzumab (sequential therapy); other risk factors for anthracycline-induced cardiotoxicity include ≥60 years of age at time of treatment and 2 or more cardiovascular risk factors (smoking, hypertension, diabetes, dyslipidemia, or obesity) during or after treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: Treatment with mitoxantrone increases the risk of developing secondary acute myeloid leukemia (AML) in patients with cancer and in patients with MS; acute promyelocytic leukemia (APL) has also been observed. Symptoms of acute leukemia include excessive bruising, bleeding and recurrent infections. The risk for secondary leukemia is increased in patients who are heavily pretreated, with higher doses, and/or with combination chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Rapid lysis of tumor cells may lead to hyperuricemia and tumor lysis syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: May contain sodium metabisulfite; use caution in patients with asthma or a sulfite allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: For IV administration only; do not administer subcutaneously, intramuscularly, or intra-arterially. Do not administer intrathecally; may cause serious and permanent neurologic damage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Blue-green coloration: May cause urine, saliva, tears, and sweat to turn blue-green for 24 hours postinfusion; whites of eyes may have blue-green tinge.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid live-attenuated vaccines in patients who currently receive or have recently discontinued mitoxantrone for multiple sclerosis; consider using live-attenuated vaccines only if risk of infection is high and killed vaccines are unavailable (AAN [Farez 2019]).</p></div>
<div class="block foc drugH1Div" id="F197544"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/10 mL (10 mL); 25 mg/12.5 mL (12.5 mL); 30 mg/15 mL (15 mL)</p></div>
<div class="block geq drugH1Div" id="F197529"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323431"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (mitoXANTRONE HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/10 mL (per mL): $20.71 - $48.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/12.5 mL (per mL): $20.71 - $54.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg/15 mL (per mL): $20.71 - $51.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867596"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (10 mL)</p></div>
<div class="block adm drugH1Div" id="F197547"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For IV administration only; do not administer intrathecally, subcutaneously, intramuscularly, or intra-arterially. Must be diluted prior to use. Usually administered as a short IV infusion over 5 to 15 minutes; do not infuse over less than 3 to 5 minutes. Mitoxantrone was infused over 20 to 30 minutes in some (off-label) regimens; refer to protocol for infusion details.</p>
<p style="text-indent:-2em;margin-left:2em;">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane or dimethyl sulfate [DMSO]). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (ESMO/EONS [Pérez Fidalgo 2012]); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dexrazoxane:</i> 1,000 mg/m<sup>2</sup> (maximum dose: 2,000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m<sup>2</sup> (maximum dose: 1,000 mg) IV over 1 to 2 hours day 3; begin within 6 hours of extravasation. Day 2 and day 3 doses should be administered at approximately the same time (±3 hours) as the dose on day 1 (ESMO/EONS [Pérez Fidalgo 2012]; Mouridsen 2007). <b>Note:</b> Reduce dexrazoxane dose by 50% in patients with moderate to severe renal impairment (CrCl &lt;40 mL/minute).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DMSO:</i> Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (ESMO/EONS [Pérez Fidalgo 2012]).</p></div>
<div class="block admp drugH1Div" id="F52613355"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: For IV administration only; do not administer by SubQ, IM, intrathecal, or intra-arterial injection. Must be diluted prior to use; may administer by IV bolus over 5 to 15 minutes or IV intermittent infusion over 15 to 60 minutes; refer to protocol for infusion details.</p>
<p style="text-indent:-2em;margin-left:4em;">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dimethyl sulfate [DMSO] <b>or</b> dexrazoxane [Adults]) (see Management of Drug Extravasations for more details). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (ESMO/EONS [Pérez Fidalgo 2012]); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p></div>
<div class="block hazard drugH1Div" id="F49132772"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block meg drugH1Div" id="F13934999"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2012%2F019297s035mg.pdf&amp;token=u36UyQ%2Bi4KN3nyKkIJFgroUgKhJjhdluVqEMQCFQSEUMwzvlSvmS51507s71d69RavHde9iX0LI8AmeZ6l4cB26%2FJKpMXu6vSxpiBxjRg4c%3D&amp;TOPIC_ID=9660" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035mg.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F197545"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemias:</b> Initial treatment (in combination with other agents) of acute nonlymphocytic leukemia (ANLL [includes myelogenous, promyelocytic, monocytic and erythroid leukemias]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, relapsing or secondary progressive:</b> Treatment of secondary (chronic) progressive, progressive relapsing, or worsening or relapsing-remitting multiple sclerosis (RRMS) to reduce neurologic disability and/or the frequency of clinical relapse.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitation of use: Mitoxantrone is not indicated for the treatment of primary progressive MS. Reserve use for rapidly-advancing, refractory multiple sclerosis (AAN [Rae-Grant 2018]; Olek 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, advanced, castrate-resistant:</b> Treatment of advanced hormone-refractory (castrate-resistant) prostate cancer (in combination with corticosteroids).</p></div>
<div class="block off-label drugH1Div" id="F25730513"><span class="drugH1">Use: Off-Label: Adult</span><p>Acute lymphoblastic leukemia, relapsed/refractory; Acute myeloid leukemia, relapsed/refractory; Acute promyelocytic leukemia, newly diagnosed; Hodgkin lymphoma; Non-Hodgkin lymphomas, relapsed/refractory; T-cell prolymphocytic leukemia</p></div>
<div class="block mst drugH1Div" id="F197627"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MitoXANTRONE may be confused with methotrexate, mitoMYcin, mitotane, MTX Patch, Mutamycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F197613"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F197538"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of MitoXANTRONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308387"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pregnancy status should be evaluated prior to treatment in patients who could become pregnant. Mitoxantrone is associated with amenorrhea, ovarian failure, and male infertility (AAN [Rae-Grant 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are stopped prior to a planned pregnancy except in patients at high risk of MS activity (AAN [Rae-Grant 2018]). Consider use of agents other than mitoxantrone for patients at high risk of disease reactivation who are planning to become pregnant. Delaying pregnancy is recommended for patients with persistent high disease activity; when disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]).</p></div>
<div class="block pri drugH1Div" id="F197553"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and adverse events observed in animal reproduction studies, mitoxantrone may cause fetal harm if administered during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of mitoxantrone during pregnancy are limited (Amato 2015; Frau 2018; Houtchens 2013; Karagiannis 2021; NTP 2013).</p>
<p style="text-indent:0em;margin-top:2em;">In general, disease-modifying therapies for multiple sclerosis (MS) are not initiated during pregnancy, except in patients at high risk of MS activity (AAN [Rae-Grant 2018]). When disease-modifying therapy is needed in these patients, other agents are preferred (ECTRIMS/EAN [Montalban 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p></div>
<div class="block brc drugH1Div" id="F197554"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Mitoxantrone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Mitoxantrone concentrations in breast milk were evaluated in a female following treatment for acute promyelocytic leukemia. The patient was administered mitoxantrone 6 mg/m<sup>2</sup> for 3 days as part of consolidation therapy. Therapy was initiated during pregnancy; breast milk was sampled after the third dose of the third consolidation treatment postpartum. The highest milk concentrations (120 ng/mL) occurred following mitoxantrone administration; significant concentrations (18 ng/mL) were still observed 28 days after the last dose (Azuno 1995). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued before starting mitoxantrone treatment.</p></div>
<div class="block mop drugH1Div" id="F197542"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential (frequently when used to treat cancer; prior to each dose when treating multiple sclerosis [MS]), serum uric acid (for leukemia treatment), LFTs. Evaluate pregnancy status (prior to treatment in patients who can become pregnant; prior to each dose in patients with MS). Monitor for infections due to neutropenia, and for signs/symptoms of tumor lysis syndrome or secondary malignancies. For the treatment of MS, latent infection screening (eg, hepatitis, tuberculosis) in high-risk populations or in countries with high tuberculosis burden (at baseline). Monitor injection site for extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac monitoring:</b> Prior to initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and ECG; evaluate baseline and periodic left ventricular ejection fraction (LVEF) with echocardiogram or multigated radionuclide angiography (MUGA) or MRI. In patients with MS, evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) prior to each dose and if signs/symptoms of HF develop. Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Additional cardiovascular monitoring to consider in patients receiving mitoxantrone for the treatment of cancer (ASCO [Armenian 2017], </i>
<i>ESC [Lyon 2022]):</i> Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking. Echocardiogram (transthoracic preferred, perform at baseline and 12 months after therapy completion for all patients; in addition, perform every 2 cycles and within 3 months after therapy completion for high-risk or very high-risk patients). Cardiac biomarkers (troponin and natriuretic peptide at baseline for high-risk and very high-risk patients [may consider for low- and moderate-risk patients]; also prior to each cycle during anthracycline treatment and at 3 and 12 months after therapy completion for high-risk and very high-risk patients). In patients who develop signs/symptoms of cardiac dysfunction during therapy, an echocardiogram is recommended for diagnostic workup; if an echocardiogram is not available or feasible, a cardiac MRI (preferred) or MUGA scan may be utilized; obtain serum cardiac biomarkers. Refer to a cardiologist when clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oncology uses:</b> The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F197532"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mitoxantrone is an anthracenedione, which is related to the anthracyclines. Mitoxantrone intercalates into DNA resulting in cross-links and strand breaks; binds to nucleic acids and inhibits DNA and RNA synthesis by template disordering and steric obstruction; replication is decreased by binding to DNA topoisomerase II and may inhibit the incorporation of uridine into RNA and thymidine into DNA; mitoxantrone is active throughout entire cell cycle (cell-cycle nonspecific).</p></div>
<div class="block phk drugH1Div" id="F197549"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: &gt;1,000 L/m<sup>2</sup>. Mitoxantrone distributes extensively into kidney, liver, heart, lung, and bone marrow, but does not cross the blood brain barrier (Perry 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 78%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 23 to 215 hours (median: ~75 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (25%); urine (11%; 65% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51159654"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: Clearance is reduced in patients with hepatic impairment. The AUC is at least 3 times greater in patients with severe hepatic impairment (bilirubin &gt;3.4 mg/dL) compared to patients with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F197555"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fada mitoxantrona | Metrisone</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ebexantron | Mitoxantron accord | Novantron konz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Mitozantrone | Mitozantrone Ebewe | Mitozantrone hydrochloride | Novantrone | Onkotrone</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone accord | Novantrone</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Evomixan | Misostol | Novantrone</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Misostol | Mitoxantrone</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Heng en | Militant | Mitoxantrone | Novantrone</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Formyxan | Mitoxantrona</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Refador</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron accord | Mitoxantron Hexal | Mitoxantron Kohne | Mitoxantron NC | Mitoxantron-GRY | Neoxantron | Onkoxantron</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Formyxan | Misostol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone accord | Novantrone | Onkotrone</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone ebewe | Novatrone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrona accord | Mitoxantrona sandoz | Novantrone</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron accord | Novantrone</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Elsep | Mitoxantrone accord | Mitoxantrone ebewe | Mitoxantrone teva | Novantrone</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone | Novantrone | Onkotrone | Trav mitoxantrone | Trav mitozantrone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Genefadrone | Novantrone</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron ebewe</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone accord | Novantrone | Refador</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Novantrone</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Nitrol | Oncotron</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone | Mitoxantrone accord | Mitoxantrone crinos | Mitoxantrone provvisoria | Novantrone | Onkotrone</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Genefadrone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Novantron</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mitron | Novantrone | Santron</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron | Mitoxantrone baxter</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron | Novantrone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Oncotrone | Refador</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Novantrone</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Novantrone | Oncotrone | Onkotrone | Refador</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bresnix | Formyxan | Matexene | Mitoxgen | Mitroxone | Neotalem | Tonaxten</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Novantrone | Santrone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron | Mitoxantron ebewe | Novantrone</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron | Novantrone</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Mitozantrone | Onkotrone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Micraleve | Mitoxantrona</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Domitrone | Novantrone</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Mitostate | Mitoxantrona | Novantrone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron | Mitoxantron accord | Mitoxantron ebewe | Mitoxantron sandoz | Mitoxantrone | Mitoxantrone baxter | Mitoxantrone hexal | Mitoxantrone kocak | Novantrone | Oncotron | Onkotrone</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone HCL | Novantrone</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrona</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fada mitoxantrona | Mitoxantrona farmaco uruguayo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron Lens | Mitoxantrone | Mitoxantrone lans | Novantrone | Oncotrone</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron | Mitoxantrone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron ebewe | Novantrone | Onkotrone</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ebexantron | Mitoxantron accord | Novantron | Refador</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron | Refador</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Ebexantron | Mitoxantrone ebewe</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantron ebewe | Mitoxantrone kocak | Neotalem | Novantron</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone | Novantrone</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Mitolik | Mitoxantron | Onkotron</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrona filaxis | Mitoxantrona FU</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mitoxantrone hexal | Novantrone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary (USP 43-NF 38).</i> Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2045861">
<a name="2045861"></a>Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine: An Effective and Tolerable Regimen for the Treatment of Refractory Acute Myeloid Leukemia. <i>J Clin Oncol</i>. 1991;9(7):1210-1214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/2045861/pubmed" id="2045861" target="_blank">2045861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25773609">
<a name="25773609"></a>Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. <i>CNS Drugs</i>. 2015;29(3):207-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/25773609/pubmed" id="25773609" target="_blank">25773609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18467731">
<a name="18467731"></a>Aplenc R, Alonzo TA, Gerbing RB, et al. Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>J Clin Oncol</i>. 2008;26(14):2390-3295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/18467731/pubmed" id="18467731" target="_blank">18467731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2179638">
<a name="2179638"></a>Arlin Z, Case DC Jr, Moore J, et al. Randomized Multicenter Trial of Cytosine Arabinoside With Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients With Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group. <i>Leukemia</i>. 1990;4(3):177-183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/2179638/pubmed" id="2179638" target="_blank">2179638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7847330">
<a name="7847330"></a>Azuno Y, Kaku K, Fujita N, Okubo M, Kaneko T, Matsumoto N. Mitoxantrone and etoposide in breast milk. <i>Am J Hematol</i>. 1995;48(2):131-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/7847330/pubmed" id="7847330" target="_blank">7847330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25199761">
<a name="25199761"></a>Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/25199761/pubmed" id="25199761" target="_blank">25199761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21766293">
<a name="21766293"></a>Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. <i>Cancer</i>. 2012;118(3):761-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/21766293/pubmed" id="21766293" target="_blank">21766293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624235">
<a name="9624235"></a>Donelli MG, Zuchetti M, Munzone E, et al. Pharmacokinetics of Anticancer Agents in Patients With Impaired Liver Function. <i>Eur J Cancer.</i> 1998;34(1):33-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/9624235/pubmed" id="9624235" target="_blank">9624235</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Farez MF, Correale J, Armstrong MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2019;93(13):584-594. doi:10.1212/WNL.0000000000008157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/31462584/pubmed" id="31462584" target="_blank">31462584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19889622">
<a name="19889622"></a>Fernandez de Larrea C, Martinez C, Gaya A, et al. Salvage Chemotherapy With Alternating MINE-ESHAP Regimen in Relapsed or Refractory Hodgkin’s Lymphoma Followed By Autologous Stem-Cell Transplantation. <i>Ann Oncol</i>. 2010;21(6):1211-1216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/19889622/pubmed" id="19889622" target="_blank">19889622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29611885">
<a name="29611885"></a>Frau J, Coghe G, Casanova P, et al. Pregnancy planning and outcomes in patients with multiple sclerosis after mitoxantrone therapy: a monocentre assessment. <i>Eur J Neurol</i>. 2018;25(8):1063-1068. doi:10.1111/ene.13650<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/29611885/pubmed" id="29611885" target="_blank">29611885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25092781">
<a name="25092781"></a>Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. <i>J Clin Oncol</i>. 2014;32(27):3021-3032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/25092781/pubmed" id="25092781" target="_blank">25092781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21902686">
<a name="21902686"></a>Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. <i>Br J Haematol</i>. 2011;155(3):366-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/21902686/pubmed" id="21902686" target="_blank">21902686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16832677">
<a name="16832677"></a>Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, et al. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). <i>Ann Hematol</i>. 2006;85(10):717-722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/16832677/pubmed" id="16832677" target="_blank">16832677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3422260">
<a name="3422260"></a>Ho AD, Lipp T, Ehninger G, et al. Combination of Mitoxantrone and Etoposide in Refractory Acute Myelogenous Leukemia an Active and Well-Tolerated Regimen. <i>J Clin Oncol</i>. 1988;6(2):213-217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/3422260/pubmed" id="3422260" target="_blank">3422260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512246">
<a name="23512246"></a>Hopfinger G, Busch R, Pflug N, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. <i>Cancer.</i> 2013;119(12):2258-2267. doi:10.1002/cncr.27972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/23512246/pubmed" id="23512246" target="_blank">23512246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926165">
<a name="22926165"></a>Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. <i>J Neurol</i>. 2013;260(5):1202-1214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/22926165/pubmed" id="22926165" target="_blank">22926165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jeffrey LP, Chairman, National Study Commission on Cytotoxic Exposure. Position Statement. “The Handling of Cytotoxic Agents by Women Who Are Pregnant, Attempting to Conceive, or Breast-Feeding,” January 12, 1987.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12736227">
<a name="12736227"></a>Joyce RM, Regan M, Ottaway J, et al. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). <i>Ann Oncol</i>. 2003;14 Suppl 1:i21-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/12736227/pubmed" id="12736227" target="_blank">12736227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33222152">
<a name="33222152"></a>Karagiannis P, Alsdorf W, Tallarek AC, et al. Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone. <i>Br J Haematol</i>. 2021;192(2):e60-e63. doi:10.1111/bjh.17220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/33222152/pubmed" id="33222152" target="_blank">33222152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3048848">
<a name="3048848"></a>Koeller J and Eble M, “Mitoxantrone: A Novel Anthracycline Derivative,” <i>Clin Pharm</i>, 1988, 7(8):574-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/3048848/pubmed" id="3048848" target="_blank">3048848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14679131">
<a name="14679131"></a>Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. <i>Ann Oncol</i>. 2004;15(1):123-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/14679131/pubmed" id="14679131" target="_blank">14679131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19826132">
<a name="19826132"></a>Mandelli F, Vignetti M, Suciu S, et al, “Daunorubicin versus Mitoxantrone versus Idarubicin as Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10,” <i>J Clin Oncol</i>, 2009, 27(32):5397-403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/19826132/pubmed" id="19826132" target="_blank">19826132</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mitoxantrone [prescribing information]. Lake Forest, IL: Hospira Inc; April 2021.</div>
</li>
<li>
<div class="reference">
                  Mitoxantrone [prescribing information]. Lake Zurich, IL: Frenesius-Kabi; October 2016.</div>
</li>
<li>
<div class="reference">
                  Mitoxantrone [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29352526">
<a name="29352526"></a>Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in <i>Eur J Neurol</i>. 2018;25(3):605]. <i>Eur J Neurol</i>. 2018;25(2):215-237. doi:10.1111/ene.13536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/29352526/pubmed" id="29352526" target="_blank">29352526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17185744">
<a name="17185744"></a>Mouridsen HT, Langer SW, Buter J, et al. Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies. <i>Ann Oncol</i>. 2007;18(3):546-550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/17185744/pubmed" id="17185744" target="_blank">17185744</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Toxicology Program (NTP) Monograph on Developmental Effects and Pregnancy Outcomes Associated with Cancer Chemotherapy Use during Pregnancy, May 2013. <a href="http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html" target="_blank">http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html</a>
</div>
</li>
<li>
<div class="reference">
                  Novantrone (mitoxantrone) [prescribing information]. Rockland, MA: Serono; May 2010.</div>
</li>
<li>
<div class="reference">
                  Olek MJ, Mowry E. Treatment of progressive multiple sclerosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 3, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234524">
<a name="16234524"></a>Ortega JJ, Madero L, Martin G, et al. Treatment With All-<i>Trans</i> Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group. <i>J Clin Oncol</i>. 2005;23(30):7632-7640.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/16234524/pubmed" id="16234524" target="_blank">16234524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21131038">
<a name="21131038"></a>Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. <i>Lancet</i>. 2010;376(9757):2009-2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/21131038/pubmed" id="21131038" target="_blank">21131038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24 Suppl 6:vi160-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12065553">
<a name="12065553"></a>Perel Y, Auvrignon A, Leblanc T, et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant. <i>J Clin Oncol</i>. 2002;20(12):2774-2782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/12065553/pubmed" id="12065553" target="_blank">12065553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Perry MC. Chemotherapeutic agents: Mitoxantrone. <i>The Chemotherapy Source Book</i>. 5th ed. Lippincott Williams &amp; Wilkins; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15470214">
<a name="15470214"></a>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and Estramustine Compared With Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. <i>N Engl J Med</i>. 2004;351(15):1513-1520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/15470214/pubmed" id="15470214" target="_blank">15470214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3700039">
<a name="3700039"></a>Pratt CB, Vietti TJ, Etcubanas E, et al. Novantrone® for Childhood Malignant Solid Tumors. A Pediatric Oncology Group Phase II Study. <i>Invest New Drugs</i>. 1986;4(1):43-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/3700039/pubmed" id="3700039" target="_blank">3700039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rae-Grant.2018">
<a name="Rae-Grant.2018"></a>Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. https://download.lww.com/wolterskluwer_vitalstream_com/PermaLink/WNL/A/WNL_2018_04_19_RAEGRANT_NEUROLOGY2017835181R1_SDC3.pdf. Published April 2018. Accessed January 29, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14576047">
<a name="14576047"></a>Sanz MA, Martin G, Gonzalez M, et al. Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group. <i>Blood</i>. 2004;103(4):1237-1243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/14576047/pubmed" id="14576047" target="_blank">14576047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20393132">
<a name="20393132"></a>Sanz MA, Montesinos P, Rayón C, et al; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood.</i> 2010;115(25):5137-5146. doi:10.1182/blood-2010-01-266007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/20393132/pubmed" id="20393132" target="_blank">20393132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990618">
<a name="31990618"></a>Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. <i>J Clin Oncol</i>. 2020;38(15):1736-1743. doi:10.1200/JCO.19.03148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/31990618/pubmed" id="31990618" target="_blank">31990618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8352235">
<a name="8352235"></a>Schiller G, Lee M, Territo M, Gajewski J, Nimer S. Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. <i>Am J Hematol.</i> 1993;43(3):195-199. doi:10.1002/ajh.2830430307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/8352235/pubmed" id="8352235" target="_blank">8352235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9576193">
<a name="9576193"></a>Stevens RF, Hann IM, Wheatley K, et al. Marked Improvements in Outcome With Chemotherapy Alone in Paediatric Acute Myeloid Leukemia: Results of the United Kingdom Medical Research Council's 10th AML Trial. MRC Childhood Leukaemia Working Party. <i>Br J Haematol</i>. 1998;101(1):130-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/9576193/pubmed" id="9576193" target="_blank">9576193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15470213">
<a name="15470213"></a>Tannock IF, de Wit R, Berry WR, et al. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer. <i>N Engl J Med</i>. 2004;351(15):1502-1512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/15470213/pubmed" id="15470213" target="_blank">15470213</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19586937">
<a name="19586937"></a>Vitolo U, Chiappella A, Angelucci E, et al. Dose-Dense and High-Dose Chemotherapy Plus Rituximab With Autologous Stem Cell Transplantation for Primary Treatment of Diffuse Large B-Cell Lymphoma With a Poor Prognosis: A Phase II Multicenter Study. <i>Haematologica</i>. 2009;94(9):1250-1258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/19586937/pubmed" id="19586937" target="_blank">19586937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8823326">
<a name="8823326"></a>Weiss M, Maslak P, Feldman E, et al. Cytarabine With High-Dose Mitoxantrone Induces Rapid Complete Remissions in Adult Acute Lymphoblastic Leukemia Without the Use of Vincristine or Prednisone. <i>J Clin Oncol</i>. 1996;14(9):2480-2485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/8823326/pubmed" id="8823326" target="_blank">8823326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12885813">
<a name="12885813"></a>Wells RJ, Adams MT, Alonzo TA, et al. Mitoxantrone and Cytarabine Induction, High-Dose Cytarabine, and Etoposide Intensification for Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia: Children's Cancer Group Study 2951. <i>J Clin Oncol</i>. 2003;21(15):2940-2947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/12885813/pubmed" id="12885813" target="_blank">12885813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18076637">
<a name="18076637"></a>Wierzbowska A, Robak T, Pluta A, et al. Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group. <i>Eur J Haematol.</i> 2008;80(2):115-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/18076637/pubmed" id="18076637" target="_blank">18076637</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9660 Version 286.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
